Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...

The second most common cancer among men is prostate cancer, affecting 1 in 8 men. Prostate cancer is treatable, in most cases, when the cancer remains localized to the prostate gland. But if the ...

Patients treated with Xofigo-Xtandi experienced a 5.6-month boost to median OS over those treated with Xtandi alone.

The American Cancer Society estimates that more than 313,780 cases of prostate cancer will be diagnosed in the United States in 2025, resulting in approximately 35,770 deaths. Bone metastasis - a ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...

TTUHSC researcher Srinivas Nandana, Ph.D., (left) and co-investigator Manisha Tripathi, Ph.D., received a grant from the U.S. Department of Defense to investigate the role of TBX2 in establishing the ...

LOWCOUNTRY, S.C. (WCIV) — In light of Former President Joe Biden's recent prostate cancer diagnosis, medical professional Dr. David Geier joined "Good Morning Charleston" Monday to discuss the ...

Former President Joe Biden was diagnosed with an “aggressive form” of prostate cancer that has a five-year survival rate of between 30% and 40%. The former president’s prostate cancer is characterized ...

Bayer’s XOFIGO® plus enzalutamide demonstrates significant OS benefit in PEACE-3 trial in patients with mCRPC with bone metastases ...

Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...